USP9X Inhibition Improves Gemcitabine Sensitivity in Pancreatic Cancer by Inhibiting Autophagy

Tao Ma,Wei Chen,Xiao Zhi,Hao Liu,Yue Zhou,Brayant Wei Chen,Liqiang Hu,Jian Shen,Xiaoxiao Zheng,Shufen Zhang,Bo Zhang,Haijun Li,Tingbo Liang

DOI: https://doi.org/10.1016/j.canlet.2018.08.010

IF: 9.756

2018-01-01

Cancer Letters

Abstract:Gemcitabine is the cornerstone of pancreatic cancer treatment. Although effective in most patients, development of tumor resistance to gemcitabine can critically limit its efficacy. The mechanisms responsible for this phenomenon remain elusive, but evidence suggests that ubiquitin-specific peptidases (USPs) may be key regulators in cancer chemo-resistance. The present study aimed to investigate the role of USP9X in gemcitabine resistance using in vitro pancreatic cell lines and a mouse xenograft model. We found that the expression of USP9X in pancreatic cancer cells was positively correlated with gemcitabine resistance, and that inhibition of USP9X by WP1130 sensitized pancreatic cancer cells to gemcitabine. Gemcitabine induced autophagy, and blocking autophagy with chloroquine improved sensitivity to gemcitabine. We also found that WP1130 inhibited gemcitabine-induced autophagy, and blocking autophagy abolished the sensitization effect of WP1130 on gemcitabine in pancreatic cancer cells. Finally, combined gemcitabine and WP1130 treatment enhanced the anti-tumor effect of gemcitabine by suppressing autophagy in vivo. Taken together, these results demonstrate that inhibition of USP9X sensitized pancreatic cancer cells to gemcitabine by inhibiting autophagy, which provides a novel insight into gemcitabine resistance in pancreatic cancer.